ADC Therapeutics, a Swiss Phase 2 biotech developing next-gen antibody drug conjugates for difficult cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company previously filed to raise $200 million in September 2019 but withdrew its prospectus a month later.
The Epalinges, Switzerland-based company was founded in 2011 and plans to list on the NYSE under the symbol ADCT. Morgan Stanley, BofA Securities and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
